FDA aprueba terapia biologica vs MASTOCITOMA inoperable

Masitinib (Masivet®) is approved in the USA as first line therapy for the treatment of canine mast cell tumours

Dear all,

I am delighted to announce that masitinib – the first anti cancer drug approved 2 years ago for veterinary use in Europe under the name of Masivet® - has now received marketing authorization in the USA under the name Kinavet®.

The clinical results obtained from a study on 202 dogs followed up during two years of treatment (a)(b) were submitted to the American health authorities and on the basis of these results, approval has been granted for masitinib to be indicated as first line therapy for the treatment of inoperable canine mast cell tumours, with mutated or non- mutated c-Kit. This decision from the FDA confirms the position of masitinib as an important first line option for the treatment of inoperable canine mast cell tumours, irrespective of c-Kit mutation status.

On behalf of all of my colleagues at AB Science, I should like take this opportunity to wish you a very happy new year and best wishes for 2011.